abstract: 1. The action of @entity5 on lung vessels was compared in @entity1 , @entity3 , ferrets and @entity0 using isolated perfused lungs and lobes of lungs perfused in vivo, both at constant flow, so that increases in inflow pressure at constant outflow pressure indicated increases in resistance. 2. @entity5 caused some increases in resistance in @entity1 , @entity3 and @entity0 but not ferrets. The increases were small compared with changes in the systemic circulation. Larger increases could be obtained in isolated lungs where there was no interference from rises in left atrial pressure. 3. All four species showed pulmonary vasoconstriction during @entity4 and ferret lungs were especially responsive. Thus @entity5 cannot be the mediator of @entity4 vasoconstriction in all these species. 4. @entity5 significantly increased the response to @entity4 in isolated cat and @entity0 lungs while also increasing baseline inflow pressure; the response to @entity4 was not altered in ferrets. @entity5 may therefore enhance reactivity of pulmonary vessels. 5. @entity6 , an inhibitor of @entity2 transport across cell membranes, reduced the response to @entity4 in @entity0 and ferrets more than it reduced the response to @entity5 in @entity0 or @entity7 in ferrets. Thus @entity4 pulmonary vasoconstriction probably involves transport of @entity2 .

title: Angiotensin, XXXX , @entity6 and pulmonary vessels.

answer: @entity4


abstract: 1. The action of @entity5 on lung vessels was compared in @entity1 , @entity3 , ferrets and @entity0 using isolated perfused lungs and lobes of lungs perfused in vivo, both at constant flow, so that increases in inflow pressure at constant outflow pressure indicated increases in resistance. 2. @entity5 caused some increases in resistance in @entity1 , @entity3 and @entity0 but not ferrets. The increases were small compared with changes in the systemic circulation. Larger increases could be obtained in isolated lungs where there was no interference from rises in left atrial pressure. 3. All four species showed pulmonary vasoconstriction during @entity4 and ferret lungs were especially responsive. Thus @entity5 cannot be the mediator of @entity4 vasoconstriction in all these species. 4. @entity5 significantly increased the response to @entity4 in isolated cat and @entity0 lungs while also increasing baseline inflow pressure; the response to @entity4 was not altered in ferrets. @entity5 may therefore enhance reactivity of pulmonary vessels. 5. @entity6 , an inhibitor of @entity2 transport across cell membranes, reduced the response to @entity4 in @entity0 and ferrets more than it reduced the response to @entity5 in @entity0 or @entity7 in ferrets. Thus @entity4 pulmonary vasoconstriction probably involves transport of @entity2 .

title: Angiotensin, @entity4 , XXXX and pulmonary vessels.

answer: @entity6


abstract: Thirty-eight cases of @entity4 in @entity0 35-years-old and younger, occurring in the period 1948 to 1983, are reviewed. They comprised 2.2% of 1710 cases in all ages for the same 35 year period at the Charity Hospital. @entity0 were afflicted as commonly as @entity0 . Blacks outnumbered whites 2.9:1.0. Obstruction, @entity3 , and weight loss of relatively short duration were prominent symptoms. @entity1 tended to be located distally in the stomach, and scirrhous in appearance. Histologically, @entity2 were more common than intestinal or other @entity1 . Radiographic evidence of disease was usually present in @entity0 undergoing upper gastrointestinal series. Endoscopy with biopsy was a valuable diagnostic tool. Resectability in this group was not less than that achieved for all ages, however, only one @entity0 has survived for five years. @entity1 predominated and were associated with poor survival. Earlier stage lesions in this age group appear to bear a more favorable prognosis.

title: XXXX in the young.

answer: @entity4


abstract: The expression of @entity4 (H) and @entity6 antigens on 68 @entity3 from 63 @entity0 was studied by immunohistochemical staining of tissue specimens. The pattern of antigen expression was as follows: @entity5 was expressed in normal tissue only in secretors and was expressed in the proximal but not distal colon. In @entity2 , there was net loss of @entity5 expression in the proximal and net gain in the distal colon. Some nonsecretor @entity2 tissue expressed @entity5 . Lewis expression was similar to but less strong than @entity5 . Its expression occurred only in secretors and in normal epithelium only in the proximal colon. In @entity2 there was net loss of antigen expression proximally and net gain in the distal colon. There was no expression of Lewisb in @entity2 of nonsecretors. Lewisa antigen was expressed throughout the normal colon in secretors and nonsecretors with no discernible difference between proximal and distal colon. In @entity2 , net loss of expression of Lewisa occurred throughout the colon. No inappropriate blood group expression was observed in this study. With few exceptions, H expression paralleled expression of A and B in non-0 @entity0 . @entity1 antigen expression was similar to that of the primary in most cases. Alterations in antigen expression were not clinically or histologically distinctive.

title: @entity5 and @entity6 expression in XXXX .

answer: @entity3


abstract: The expression of @entity4 (H) and @entity6 antigens on 68 @entity3 from 63 @entity0 was studied by immunohistochemical staining of tissue specimens. The pattern of antigen expression was as follows: @entity5 was expressed in normal tissue only in secretors and was expressed in the proximal but not distal colon. In @entity2 , there was net loss of @entity5 expression in the proximal and net gain in the distal colon. Some nonsecretor @entity2 tissue expressed @entity5 . Lewis expression was similar to but less strong than @entity5 . Its expression occurred only in secretors and in normal epithelium only in the proximal colon. In @entity2 there was net loss of antigen expression proximally and net gain in the distal colon. There was no expression of Lewisb in @entity2 of nonsecretors. Lewisa antigen was expressed throughout the normal colon in secretors and nonsecretors with no discernible difference between proximal and distal colon. In @entity2 , net loss of expression of Lewisa occurred throughout the colon. No inappropriate blood group expression was observed in this study. With few exceptions, H expression paralleled expression of A and B in non-0 @entity0 . @entity1 antigen expression was similar to that of the primary in most cases. Alterations in antigen expression were not clinically or histologically distinctive.

title: @entity5 and XXXX expression in @entity3 .

answer: @entity6


abstract: The expression of @entity4 (H) and @entity6 antigens on 68 @entity3 from 63 @entity0 was studied by immunohistochemical staining of tissue specimens. The pattern of antigen expression was as follows: @entity5 was expressed in normal tissue only in secretors and was expressed in the proximal but not distal colon. In @entity2 , there was net loss of @entity5 expression in the proximal and net gain in the distal colon. Some nonsecretor @entity2 tissue expressed @entity5 . Lewis expression was similar to but less strong than @entity5 . Its expression occurred only in secretors and in normal epithelium only in the proximal colon. In @entity2 there was net loss of antigen expression proximally and net gain in the distal colon. There was no expression of Lewisb in @entity2 of nonsecretors. Lewisa antigen was expressed throughout the normal colon in secretors and nonsecretors with no discernible difference between proximal and distal colon. In @entity2 , net loss of expression of Lewisa occurred throughout the colon. No inappropriate blood group expression was observed in this study. With few exceptions, H expression paralleled expression of A and B in non-0 @entity0 . @entity1 antigen expression was similar to that of the primary in most cases. Alterations in antigen expression were not clinically or histologically distinctive.

title: XXXX and @entity6 expression in @entity3 .

answer: @entity5


abstract: The presence of @entity2 -independent @entity9 receptors ( @entity10 ) was demonstrated in a subline of a @entity0 @entity8 cell line, Ishikawa cells, although the original Ishikawa cells contained @entity2 -inducible @entity10 . Scatchard plot analysis of cytoplasmic binding data in our subline (IK-90) revealed a high affinity binding site for @entity11 (Kd, 1.0 nM) with maximum binding sites of 158 fmol/mg protein. Competition experiments showed a binding specificity similar to that of typical @entity10 . By low-salt @entity7 gradient centrifugation, radioactive 8S and 4S peaks were found. The addition of 1 microM @entity9 in culture medium resulted in a rapid nuclear translocation of cytoplasmic @entity10 . In contrast to the original cells, @entity2 receptors could not be detected in IK-90 cells, and an addition of @entity1 (10 nM) to culture medium failed to increase @entity10 . Accumulation of glycogen in cytoplasm of IK-90 cells in response to @entity11 (0.1-1 microM) was observed by periodic acid-Schiff staining. The addition of @entity11 to culture medium (0.1-1 microM) also caused a marked decrease in the growth of IK-90 cells, whereas the other @entity3 including @entity1 , @entity5 , @entity4 , and @entity6 had no significant effects. These results demonstrate for the first time the presence of a progestin-responsive @entity0 @entity8 cell line that contains @entity2 -independent functional @entity10 . IK-90 cells appear to be an ideal model for studying the mechanism of the antiproliferative effect of progestin on @entity8 cells.

title: Growth inhibition by progestins in a @entity0 @entity8 cell line with XXXX -independent @entity9 receptors.

answer: @entity2


abstract: The presence of @entity2 -independent @entity9 receptors ( @entity10 ) was demonstrated in a subline of a @entity0 @entity8 cell line, Ishikawa cells, although the original Ishikawa cells contained @entity2 -inducible @entity10 . Scatchard plot analysis of cytoplasmic binding data in our subline (IK-90) revealed a high affinity binding site for @entity11 (Kd, 1.0 nM) with maximum binding sites of 158 fmol/mg protein. Competition experiments showed a binding specificity similar to that of typical @entity10 . By low-salt @entity7 gradient centrifugation, radioactive 8S and 4S peaks were found. The addition of 1 microM @entity9 in culture medium resulted in a rapid nuclear translocation of cytoplasmic @entity10 . In contrast to the original cells, @entity2 receptors could not be detected in IK-90 cells, and an addition of @entity1 (10 nM) to culture medium failed to increase @entity10 . Accumulation of glycogen in cytoplasm of IK-90 cells in response to @entity11 (0.1-1 microM) was observed by periodic acid-Schiff staining. The addition of @entity11 to culture medium (0.1-1 microM) also caused a marked decrease in the growth of IK-90 cells, whereas the other @entity3 including @entity1 , @entity5 , @entity4 , and @entity6 had no significant effects. These results demonstrate for the first time the presence of a progestin-responsive @entity0 @entity8 cell line that contains @entity2 -independent functional @entity10 . IK-90 cells appear to be an ideal model for studying the mechanism of the antiproliferative effect of progestin on @entity8 cells.

title: Growth inhibition by progestins in a @entity0 @entity8 cell line with @entity2 -independent XXXX receptors.

answer: @entity9


abstract: The presence of @entity2 -independent @entity9 receptors ( @entity10 ) was demonstrated in a subline of a @entity0 @entity8 cell line, Ishikawa cells, although the original Ishikawa cells contained @entity2 -inducible @entity10 . Scatchard plot analysis of cytoplasmic binding data in our subline (IK-90) revealed a high affinity binding site for @entity11 (Kd, 1.0 nM) with maximum binding sites of 158 fmol/mg protein. Competition experiments showed a binding specificity similar to that of typical @entity10 . By low-salt @entity7 gradient centrifugation, radioactive 8S and 4S peaks were found. The addition of 1 microM @entity9 in culture medium resulted in a rapid nuclear translocation of cytoplasmic @entity10 . In contrast to the original cells, @entity2 receptors could not be detected in IK-90 cells, and an addition of @entity1 (10 nM) to culture medium failed to increase @entity10 . Accumulation of glycogen in cytoplasm of IK-90 cells in response to @entity11 (0.1-1 microM) was observed by periodic acid-Schiff staining. The addition of @entity11 to culture medium (0.1-1 microM) also caused a marked decrease in the growth of IK-90 cells, whereas the other @entity3 including @entity1 , @entity5 , @entity4 , and @entity6 had no significant effects. These results demonstrate for the first time the presence of a progestin-responsive @entity0 @entity8 cell line that contains @entity2 -independent functional @entity10 . IK-90 cells appear to be an ideal model for studying the mechanism of the antiproliferative effect of progestin on @entity8 cells.

title: Growth inhibition by progestins in a @entity0 XXXX cell line with @entity2 -independent @entity9 receptors.

answer: @entity8


abstract: The presence of @entity2 -independent @entity9 receptors ( @entity10 ) was demonstrated in a subline of a @entity0 @entity8 cell line, Ishikawa cells, although the original Ishikawa cells contained @entity2 -inducible @entity10 . Scatchard plot analysis of cytoplasmic binding data in our subline (IK-90) revealed a high affinity binding site for @entity11 (Kd, 1.0 nM) with maximum binding sites of 158 fmol/mg protein. Competition experiments showed a binding specificity similar to that of typical @entity10 . By low-salt @entity7 gradient centrifugation, radioactive 8S and 4S peaks were found. The addition of 1 microM @entity9 in culture medium resulted in a rapid nuclear translocation of cytoplasmic @entity10 . In contrast to the original cells, @entity2 receptors could not be detected in IK-90 cells, and an addition of @entity1 (10 nM) to culture medium failed to increase @entity10 . Accumulation of glycogen in cytoplasm of IK-90 cells in response to @entity11 (0.1-1 microM) was observed by periodic acid-Schiff staining. The addition of @entity11 to culture medium (0.1-1 microM) also caused a marked decrease in the growth of IK-90 cells, whereas the other @entity3 including @entity1 , @entity5 , @entity4 , and @entity6 had no significant effects. These results demonstrate for the first time the presence of a progestin-responsive @entity0 @entity8 cell line that contains @entity2 -independent functional @entity10 . IK-90 cells appear to be an ideal model for studying the mechanism of the antiproliferative effect of progestin on @entity8 cells.

title: Growth inhibition by progestins in a XXXX @entity8 cell line with @entity2 -independent @entity9 receptors.

answer: @entity0


abstract: BACKGROUND: Despite the good prognosis of @entity4 ( @entity4 ), some @entity0 have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of @entity4 , e.g. the early interaction between Borrelia ( @entity2 and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in peripheral blood in @entity0 with @entity4 is associated with the clinical outcome. METHODS: A prospective follow-up study of 109 @entity0 with @entity4 was conducted at the   land Islands, Finland. Symptoms were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the @entity4 and healthy skin were immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-y, as well as for @entity2 DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic cytokines. FINDINGS: None of the @entity0 developed late manifestations of @entity3 . However, at the 6-month follow-up, 7 of 88 @entity0 reported persisting symptoms of diverse character. Compared to asymptomatic @entity0 , these 7 @entity0 showed decreased expression of the @entity1 -associated cytokine IFN-y in the @entity4 biopsies (p=0.003). @entity5 DNA was found in 48%, @entity6 in 15% and @entity2 in 1% of the @entity4 biopsies, and species distribution was the same in @entity0 with and without post-treatment symptoms. The two groups did not differ regarding baseline @entity0 characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels. CONCLUSION: @entity0 with persisting symptoms following an @entity4 show a decreased @entity1 -type inflammatory response in infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding supports the importance of an early, local @entity1 -type response for optimal resolution of LB.

title: Decreased @entity1 -type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of XXXX .

answer: @entity4


abstract: BACKGROUND: Despite the good prognosis of @entity4 ( @entity4 ), some @entity0 have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of @entity4 , e.g. the early interaction between Borrelia ( @entity2 and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in peripheral blood in @entity0 with @entity4 is associated with the clinical outcome. METHODS: A prospective follow-up study of 109 @entity0 with @entity4 was conducted at the   land Islands, Finland. Symptoms were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the @entity4 and healthy skin were immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-y, as well as for @entity2 DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic cytokines. FINDINGS: None of the @entity0 developed late manifestations of @entity3 . However, at the 6-month follow-up, 7 of 88 @entity0 reported persisting symptoms of diverse character. Compared to asymptomatic @entity0 , these 7 @entity0 showed decreased expression of the @entity1 -associated cytokine IFN-y in the @entity4 biopsies (p=0.003). @entity5 DNA was found in 48%, @entity6 in 15% and @entity2 in 1% of the @entity4 biopsies, and species distribution was the same in @entity0 with and without post-treatment symptoms. The two groups did not differ regarding baseline @entity0 characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels. CONCLUSION: @entity0 with persisting symptoms following an @entity4 show a decreased @entity1 -type inflammatory response in infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding supports the importance of an early, local @entity1 -type response for optimal resolution of LB.

title: Decreased XXXX -type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of @entity4 .

answer: @entity1


abstract: INTRODUCTION: Rupture of the pectoralis major muscle appears to be increasing in athletes. However, the optimal treatment strategy has not yet been established. OBJECTIVES: To compare the isokinetic shoulder performance after surgical treatment to that after non-surgical treatment for pectoralis major @entity0 . METHODS: We assessed 33 pectoralis major @entity0 (18 treated non-surgically and 15 treated surgically). Horizontal abduction and adduction as well as external and internal rotation at 60 and 120 degrees/s were tested in both upper limbs. Peak torque, total work, @entity2 , and the peak torque agonist-to-antagonist ratio were measured. RESULTS: @entity4 did not differ between the surgical and non-surgical treatment modalities. However, the surgical group presented twice the number of athletes with clinically acceptable @entity2 (<20%) for internal rotators compared to the non-surgical group. The peak torque ratio between the external and internal rotator muscles revealed a similar @entity2 in both groups and on both sides (surgical, 61.60% and 57.80% and non-surgical, 62.06% and 54.06%, for the dominant and non-dominant sides, respectively). The peak torque ratio revealed that the horizontal adduction muscles on the injured side showed similar weakness in both groups (surgical, 86.27%; non-surgical, 98.61%). CONCLUSIONS: This study included the largest single series of athletes reported to date for this @entity1 . A comparative analysis of muscular strength and balance showed no differences between the treatment modalities for pectoralis major @entity0 . However, the number of significant @entity3 was lower in the surgical group than in the non-surgical group, and both treatment modalities require greater attention to the rehabilitation process, especially for the recovery of muscle strength and balance.

title: Isokinetic muscle assessment after treatment of pectoralis major XXXX using surgical or non-surgical procedures.

answer: @entity0


abstract: PURPOSE: Previous clinical observations suggested that coffee may have beneficial effects on the liver. In fact, an inverse relationship between coffee consumption and @entity3 has been reported in @entity0 . However, the causative role of coffee has not been established; therefore, the aim of this work was to study the effect of coffee in an experimental model of @entity2 . METHODS: In this work, @entity1 was induced by chronic @entity8 administration and soluble or grain coffee (SC, GC, respectively) were co-administered for 8  weeks. RESULTS: @entity8 administration elevated serum alkaline phosphatase and @entity6 aminotranspherase, liver lipid peroxidation, collagen content (fourfold) and @entity4 mRNA, and protein levels; depleted liver glycogen and @entity5 ( @entity7 ) content. Coffee prevented most of the changes produced by @entity8 . Histopathological analysis was in agreement with biochemical and molecular data. The best effect was produced by GC. It is worth noting that GC preserved the normal collagen content as well as the normal @entity4 mRNA and protein levels. CONCLUSIONS: Our results suggest (1) that coffee plays a causative role in preventing @entity1 (at least experimental @entity1 ); (2) that action mechanisms are probably associated with down regulation of the profibrogenic cytokine @entity4 and to its antioxidant properties and, (3) that GC is more potent than SC. These findings suggest a beneficial effect of coffee on the liver. However, more clinical and basic studies must be performed before reaching a final recommendation.

title: Coffee prevents XXXX -induced @entity3 in the rat.

answer: @entity8


abstract: PURPOSE: Previous clinical observations suggested that coffee may have beneficial effects on the liver. In fact, an inverse relationship between coffee consumption and @entity3 has been reported in @entity0 . However, the causative role of coffee has not been established; therefore, the aim of this work was to study the effect of coffee in an experimental model of @entity2 . METHODS: In this work, @entity1 was induced by chronic @entity8 administration and soluble or grain coffee (SC, GC, respectively) were co-administered for 8  weeks. RESULTS: @entity8 administration elevated serum alkaline phosphatase and @entity6 aminotranspherase, liver lipid peroxidation, collagen content (fourfold) and @entity4 mRNA, and protein levels; depleted liver glycogen and @entity5 ( @entity7 ) content. Coffee prevented most of the changes produced by @entity8 . Histopathological analysis was in agreement with biochemical and molecular data. The best effect was produced by GC. It is worth noting that GC preserved the normal collagen content as well as the normal @entity4 mRNA and protein levels. CONCLUSIONS: Our results suggest (1) that coffee plays a causative role in preventing @entity1 (at least experimental @entity1 ); (2) that action mechanisms are probably associated with down regulation of the profibrogenic cytokine @entity4 and to its antioxidant properties and, (3) that GC is more potent than SC. These findings suggest a beneficial effect of coffee on the liver. However, more clinical and basic studies must be performed before reaching a final recommendation.

title: Coffee prevents @entity8 -induced XXXX in the rat.

answer: @entity3


abstract: Between 1970 and 1978 135 @entity0 with @entity2 underwent operations due to @entity3 , @entity1 , and severe @entity4 . Of them, 63% were acyanotic; 68% of all operations became necessary during the first 6 months of life. The late mortality rate was 5% and the hospital mortality rate 17%. A remarkably higher operative risk was found during the first 6 months of life. Ligation of patent ductus arteriosus as the most common lesion was done with a mortality rate of 2.5% which is comparable to the risk of late repair in childhood. Pulmonary artery banding could be performed in all @entity2 with a mortality rate of 17% and of 12.5% in isolated VSD (including debanding and VSD closure in several cases). @entity5 was corrected with a overall mortality rate of 26%. Because of a recurrence rate of 20%, the authors think that operations are only indicated in symptomatic cases of @entity5 . In @entity2 , a higher operative risk was observed in both pulmonary artery banding (38%) and shunt operations (44%). If surgical treatment is necessary, the earlier, the better.

title: [Surgical treatment of congenital heart disease in XXXX without use of extracorporeal circulation (author's transl)].

answer: @entity0


abstract: Traditionally, it has been accepted that conductive @entity2 involves a breakdown in the mechanical conduction of sound, whilst the cochlea remains unaffected. Over a ten year period, it was noticed that a number of @entity0 , mainly @entity0 , displayed a mild, high-tone sensorineural component to their conductive loss, whereas others tested under identical conditions with parallel etiologies did not. A sample of 80 @entity0 with @entity1 and sensorineural involvement was selected from Prince Henry's Hospital and Alfred Hospital, Melbourne, and was compared with 80 @entity0 with the same histories, but whose audiograms did not display any sensorineural involvement. The results of this study indicate a need for further research into: 1. The establishment of an internationally acceptable terminology. 2. Early detection of @entity1 . 3. Medical/surgical management. 4. The effects on hearing, caused by fluctuating nature of @entity1 . 5. Educational and social management.

title: A sensorineural component in XXXX .

answer: @entity1


abstract: OBJECTIVE: @entity2 is a common problem in male circumcision. We investigated the effect of nanometer @entity3 dressing (Shenzhen AGT Pharm. Co. Ltd.) in relieving @entity1 following male circumcision. METHODS: Sixty @entity0 undergoing circumcision in the outpatient department were randomized into an experimental and a control group, the incision covered with nanometer @entity3 dressing in the former and with vaseline dressing in the latter. None of the @entity0 received any analgesics or other @entity1 -killing therapies after surgery. The @entity2 intensity was accessed using the modified @entity1 intensity assessment scale at 1, 2, 3, 5 and 7 days after the operation, and statistical analyses were performed using SPSS 12.0 software. RESULTS: The @entity0 averaged (31.13 +/- 13.94) years in age, and had no significant differences in age and body mass index (BMI) between the two groups. @entity4 days, @entity2 intensity was significantly lower in the experimental than in the control group (P > 0.05). Multiple regression analysis revealed that @entity2 score was not correlated with @entity0 ' age, BMI and types of disease, but with the types of dressing. CONCLUSION: Nanometer @entity3 dressing can significantly alleviate @entity2 of circumcision, and is particularly applicable to such moist parts as the perineum, genitals, and urethra.

title: [Nanometer XXXX dressing @entity1 after circumcision].

answer: @entity3


abstract: OBJECTIVE: @entity2 is a common problem in male circumcision. We investigated the effect of nanometer @entity3 dressing (Shenzhen AGT Pharm. Co. Ltd.) in relieving @entity1 following male circumcision. METHODS: Sixty @entity0 undergoing circumcision in the outpatient department were randomized into an experimental and a control group, the incision covered with nanometer @entity3 dressing in the former and with vaseline dressing in the latter. None of the @entity0 received any analgesics or other @entity1 -killing therapies after surgery. The @entity2 intensity was accessed using the modified @entity1 intensity assessment scale at 1, 2, 3, 5 and 7 days after the operation, and statistical analyses were performed using SPSS 12.0 software. RESULTS: The @entity0 averaged (31.13 +/- 13.94) years in age, and had no significant differences in age and body mass index (BMI) between the two groups. @entity4 days, @entity2 intensity was significantly lower in the experimental than in the control group (P > 0.05). Multiple regression analysis revealed that @entity2 score was not correlated with @entity0 ' age, BMI and types of disease, but with the types of dressing. CONCLUSION: Nanometer @entity3 dressing can significantly alleviate @entity2 of circumcision, and is particularly applicable to such moist parts as the perineum, genitals, and urethra.

title: [Nanometer @entity3 dressing XXXX after circumcision].

answer: @entity1


abstract: INTRODUCTION: @entity4 is a significant health problem in adolescent age group and severe cases may require admission and blood transfusion. Aim of this study was to evaluate the causes, associated complications and management of @entity4 . METHODS: Hospital records of all @entity0 of @entity4 requiring admission were analyzed for etiology, duration since menarche, duration of @entity2 , investigation profile and management. RESULTS: There were 18 @entity0 of @entity4 requiring hospital admission. Etiology was @entity2 in 11 @entity0 , @entity8 in five which included @entity3 in three and one each with @entity7 and @entity6 . Two @entity0 had @entity5 as the cause. Fourteen @entity0 presented with severe @entity1 and required blood transfusion. All except one responded to oral hormonal therapy. CONCLUSIONS: @entity4 can be associated with severe complications and requiring blood transfusion. Although most common cause is anovulation but @entity8 , other medical condition and other organic causes must be ruled out in any @entity0 of @entity4 .

title: XXXX requiring inpatient admission.

answer: @entity4


abstract: @entity6 ( @entity6 ) is the most devastating @entity8 , leading to progressive @entity3 of respiratory (e.g. diaphragm) and locomotor muscles (e.g. gastrocnemius). @entity6 is caused by @entity5 in the gene that encodes for @entity9 , a key scaffolding protein of the dystroglycan complex (DCG) within the sarcolemmal cytoskeleton. As a result of a compromised dystroglycan complex, mechanical integrity is impaired and important signalling proteins (e.g. @entity7 , @entity11 ) and pathways are disrupted. Disruption of the dystroglycan complex leads to high susceptibility to injury with repeated, eccentric contractions as well as @entity0 , resulting in significant damage and @entity1 . @entity10 and repair cycling leads to @entity2 and @entity3 . While the link between @entity0 with damage and @entity3 in the @entity6 diaphragm is unresolved, elevated oxidative stress may contribute to damage, @entity3 and possibly @entity2 . While utilization of non-specific antioxidant interventions has yielded inconsistent results, recent data suggest that @entity4 oxidase could play a pivotal role in elevating oxidative stress via integrated changes in @entity11 and stretch-activated channels (SACs). Oxidative stress may act as an amplifier, exacerbating disruption of the dystroglycan complex, upregulation of the inflammatory transcription factor NF-B, and thus functional impairment of force-generating capacity.

title: Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with XXXX .

answer: @entity6


abstract: 1. The occurrence of @entity5 , a new polypeptide from amphibian skin, and its actions on @entity0 blood pressure and diuresis were studied. 2. @entity5 was found to be present in the skin of all the 10 Phyllomedusa species so far studied, amounts ranging from a few micrograms to 240 micrograms per g fresh skin. 3. The polypeptide displayed in the @entity0 an intense, long-lasting @entity1 action accompanied by @entity2 . @entity1 was not modified by either @entity4 or @entity3 , excluding the participation of the autonomic nervous system in its production. @entity2 , on the contrary, was partially inhibited by @entity3 . 4. @entity1 is probably the main cause of the intense antidiuresis seen in hydrated @entity0 following @entity5 administration. Reduction in urina volume was accompanied by a decrease in GFR and an increase in tubular NA+ reabsorption.

title: XXXX , a new polypeptide from Phyllomedusa sauvagei skin. Occurrence in various Phyllomedusa species and pharmacological actions on @entity0 blood pressure and diuresis.

answer: @entity5


abstract: 1. The occurrence of @entity5 , a new polypeptide from amphibian skin, and its actions on @entity0 blood pressure and diuresis were studied. 2. @entity5 was found to be present in the skin of all the 10 Phyllomedusa species so far studied, amounts ranging from a few micrograms to 240 micrograms per g fresh skin. 3. The polypeptide displayed in the @entity0 an intense, long-lasting @entity1 action accompanied by @entity2 . @entity1 was not modified by either @entity4 or @entity3 , excluding the participation of the autonomic nervous system in its production. @entity2 , on the contrary, was partially inhibited by @entity3 . 4. @entity1 is probably the main cause of the intense antidiuresis seen in hydrated @entity0 following @entity5 administration. Reduction in urina volume was accompanied by a decrease in GFR and an increase in tubular NA+ reabsorption.

title: @entity5 , a new polypeptide from Phyllomedusa sauvagei skin. Occurrence in various Phyllomedusa species and pharmacological actions on XXXX blood pressure and diuresis.

answer: @entity0


abstract: AIM: The aim of this study was to provide basic representative data on the prevalence of @entity3 involving @entity4 in both primary and early mixed dentition and to examine the relationship between these @entity3 and @entity1 . The results should be viewed from an orthodontic prevention and early treatment perspective. SUBJECTS AND METHODS: Orthodontic findings in the maxilla and mandible as well as the myofunctional status of 766 @entity0 in primary dentition and 2,209 @entity0 in mixed dentition were examined clinically in a cross-sectional study. The following parameters from each jaw were subjected to orthodontic analysis: crowding in the anterior and posterior regions of the maxilla and mandible in primary and mixed dentitions, deviations from normal maxillary arch forms in the primary dentition, deviations from normal anterior maxillary arch width in mixed dentition and maxillary apical base morphology in mixed dentition. Static and dynamic @entity1 were documented with reference to specific parameters and clinical tests. RESULTS: Crowding was observed in every tenth @entity0 in primary dentition (10.8%) and in every second @entity0 in mixed dentition (49.7%). @entity2 posture, visceral swallowing, @entity5 and oral habits were statistically significantly more frequent in @entity0 in primary dentition presenting a narrow maxillary arch. Reduced anterior maxillary arch width (compression) was statistically more frequent in @entity0 in early mixed dentitions with @entity2 posture. A narrow maxillary apical base correlated positively with all the @entity1 analyzed. CONCLUSIONS: Deviations from a regular arch form become apparent very early during dentition development and coexist with specific @entity1 . They are thus important indicators for the early detection of functional abnormalities, causing deviations from normal dentition development. In @entity0 with @entity1 the development of a narrow maxillary dental arch should be prevented by myofunctional therapy and by educating the parents. Interceptive orthodontic measures to treat a narrow maxillary arch in primary and early mixed dentition should also focus on eliminating functional disturbing factors, such as @entity1 . Interdisciplinary cooperation with specialists in other fields of medicine, e.g. otorhinolaryngology and speech therapy, is essential to achieve this goal.

title: Relationship between occlusal findings and orofacial myofunctional status in primary and mixed dentition: part IV: interrelation between space conditions and XXXX .

answer: @entity1


abstract: CCN proteins are important modulators of development and function of adult organs. In this study, we examined the localization and expression of the six CCN family members in normal adult @entity0 skin and during wound healing in vivo. Transcript and protein expression were studied by laser-capture microdissection-coupled real-time PCR and immunohistochemistry, respectively. Our results demonstrate that @entity2 , @entity6 , and @entity5 are expressed at relatively low levels in normal @entity0 skin. @entity3 , @entity4 , and @entity1 are the most highly expressed transcripts in the epidermis. @entity4 and @entity1 proteins are prominent in epidermal keratinocytes, whereas @entity3 is primarily expressed in melanocytes. Differential expression within epidermal layers suggests that @entity4 and @entity1 are linked with keratinocyte differentiation. @entity3 , @entity4 and @entity1 , are the three most highly expressed transcripts in the dermis. Their respective proteins are produced to various extents by dermal fibroblasts, blood vessels, eccrine sweat glands and hair follicles. We find that most CCN family members are temporally and specifically regulated during different phases (inflammation, proliferation, and remodeling) of partial thickness wound repair. By highlighting spatial-temporal regulations of CCN family member expression in relation to cell proliferation and differentiation, our results suggest a diverse range of functions for CCN proteins in both epidermal and dermal cells, and provides a solid reference for interpretation of future studies aimed at understanding the role of CCN proteins in @entity0 skin physiology and diseases.

title: Spatial-temporal modulation of CCN proteins during wound healing in XXXX skin in vivo.

answer: @entity0


abstract: BACKGROUND: @entity3 ( @entity3 ) is a potent eosinophil chemotactic and activating peptide that may be implicated in the pathogenesis of @entity1 and has been associated with the wearing of contact lenses (CL) in @entity0 with @entity2 ( @entity2 ). The purpose of this study was to study @entity3 expression in the tears of long-term CL wearers. @entity0 AND METHODS: Tears were collected with glass capillaries from 15 @entity0 (2 male, 13 female) with various degree of @entity2 at 2-year intervals. @entity2 severity was graded from 0 to 4 with reference to standard slit-lamp photographs of the superior tarsal conjunctiva. The @entity3 level in the tears was measured by an ELISA, using mouse anti-human eotaxin monoclonal antibodies. RESULTS: The mean age was 32.5    13.3 years (range: 17 - 69 years). The mean interval between the tear collections was 30    4.8 months. The mean concentration of eotaxin was 2150    477 pg/mL and 2486    810 pg/mL for the first and second series, respectively. The difference was not statistically significant (paired Wilcoxon/Kruskal-Wallis, p = 0.803). The mean score of papilla grade was 1.26    0.18 for the first sample and 1.40    0.19 two years later. There was no significant difference of grading between the two time periods (paired Wilcoxon/Kruskal-Wallis, p = 0.751). CONCLUSIONS: the @entity3 level remains up-regulated over a long time period in @entity0 wearing CL, most of them with chronic @entity2 . Eotaxin may play a role in the pathogenesis of contact lens intolerance.

title: Persistence of increased XXXX ( @entity3 ) level in tears of @entity0 wearing contact lenses: a long-term follow-up study.

answer: @entity3


abstract: BACKGROUND: @entity3 ( @entity3 ) is a potent eosinophil chemotactic and activating peptide that may be implicated in the pathogenesis of @entity1 and has been associated with the wearing of contact lenses (CL) in @entity0 with @entity2 ( @entity2 ). The purpose of this study was to study @entity3 expression in the tears of long-term CL wearers. @entity0 AND METHODS: Tears were collected with glass capillaries from 15 @entity0 (2 male, 13 female) with various degree of @entity2 at 2-year intervals. @entity2 severity was graded from 0 to 4 with reference to standard slit-lamp photographs of the superior tarsal conjunctiva. The @entity3 level in the tears was measured by an ELISA, using mouse anti-human eotaxin monoclonal antibodies. RESULTS: The mean age was 32.5    13.3 years (range: 17 - 69 years). The mean interval between the tear collections was 30    4.8 months. The mean concentration of eotaxin was 2150    477 pg/mL and 2486    810 pg/mL for the first and second series, respectively. The difference was not statistically significant (paired Wilcoxon/Kruskal-Wallis, p = 0.803). The mean score of papilla grade was 1.26    0.18 for the first sample and 1.40    0.19 two years later. There was no significant difference of grading between the two time periods (paired Wilcoxon/Kruskal-Wallis, p = 0.751). CONCLUSIONS: the @entity3 level remains up-regulated over a long time period in @entity0 wearing CL, most of them with chronic @entity2 . Eotaxin may play a role in the pathogenesis of contact lens intolerance.

title: Persistence of increased @entity3 ( XXXX ) level in tears of @entity0 wearing contact lenses: a long-term follow-up study.

answer: @entity3


abstract: BACKGROUND: @entity3 ( @entity3 ) is a potent eosinophil chemotactic and activating peptide that may be implicated in the pathogenesis of @entity1 and has been associated with the wearing of contact lenses (CL) in @entity0 with @entity2 ( @entity2 ). The purpose of this study was to study @entity3 expression in the tears of long-term CL wearers. @entity0 AND METHODS: Tears were collected with glass capillaries from 15 @entity0 (2 male, 13 female) with various degree of @entity2 at 2-year intervals. @entity2 severity was graded from 0 to 4 with reference to standard slit-lamp photographs of the superior tarsal conjunctiva. The @entity3 level in the tears was measured by an ELISA, using mouse anti-human eotaxin monoclonal antibodies. RESULTS: The mean age was 32.5    13.3 years (range: 17 - 69 years). The mean interval between the tear collections was 30    4.8 months. The mean concentration of eotaxin was 2150    477 pg/mL and 2486    810 pg/mL for the first and second series, respectively. The difference was not statistically significant (paired Wilcoxon/Kruskal-Wallis, p = 0.803). The mean score of papilla grade was 1.26    0.18 for the first sample and 1.40    0.19 two years later. There was no significant difference of grading between the two time periods (paired Wilcoxon/Kruskal-Wallis, p = 0.751). CONCLUSIONS: the @entity3 level remains up-regulated over a long time period in @entity0 wearing CL, most of them with chronic @entity2 . Eotaxin may play a role in the pathogenesis of contact lens intolerance.

title: Persistence of increased @entity3 ( @entity3 ) level in tears of XXXX wearing contact lenses: a long-term follow-up study.

answer: @entity0


abstract: BACKGROUND: The epidemiologic study of @entity2 is problematic and differing incidences across the world are reported. In Tunisia, the incidence of this affection is yet unknown. This is at least attributable to the lack of large series and the overshadowing presence of @entity3 . AIM: To determine presenting signs, symptoms and investigations particularities. METHODS: We report a retrospective series @entity0 with @entity2 followed up in the Rabta university hospital between 1991 and 2005 and try to determine presenting signs, symptoms and investigations particularities. RESULTS: 131 @entity0 (79 @entity0 and 52 @entity0 ) with a median age of 47    14 years were reviewed. They were symptomatic in 95 % of cases. @entity4 were present at onset in 56.8 %, respiratory symptoms in 48.6 % and general symptoms in 41.6 %. Thoracic presentation was observed in 81.3%. Chest X-ray changes and tomodensitometry showed that type II and III were predominant. Lung function was disturbed in 58.5% of the cases. Extrathoracic involvement, observed in 89.3 % of the cases, was largely dominated by cutaneous lesions. @entity1 provided diagnosis in 66.6%. CONCLUSION: The relative high frequency of dermatological lesions suggests genetic or even environmental predisposition to develop @entity2 such as sunlight exposition.

title: [ XXXX in Tunisia: epidemiologic and clinical study].

answer: @entity2


abstract: Intense efforts are underway to evaluate neuroimaging measures as biomarkers for @entity0 in premanifest @entity2 (preHD). We used a completely automated longitudinal analysis method to compare structural scans in preHD individuals and controls. Using a 1-year longitudinal design, we analyzed T(1) -weighted structural scans in 35 preHD individuals and 22 age-matched controls. We used the SIENA (Structural Image Evaluation, using Normalization, of Atrophy) software tool to yield overall percentage brain volume change (PBVC) and voxel-level changes in @entity1 . We calculated sample sizes for a hypothetical disease-modifying (neuroprotection) study. We found significantly greater yearly @entity1 in preHD individuals versus controls (mean PBVC controls, -0.149%; preHD, -0.388%; P = .031, Cohen's d = .617). For a preHD subgroup closest to disease onset, yearly @entity1 was more than 3 times that of controls (mean PBVC close-to-onset preHD, -0.510%; P = .019, Cohen's d = .920). This @entity1 was evident at the voxel level in periventricular regions, consistent with well-established preHD basal ganglia @entity1 . We estimated that a neuroprotection study using SIENA would only need 74 close-to-onset individuals in each arm (treatment vs placebo) to detect a 50% slowing in yearly @entity1 with 80% power. Automated whole-brain analysis of structural MRI can reliably detect preHD disease progression in 1 year. These results were attained with a readily available imaging analysis tool, SIENA, which is observer independent, automated, and robust with respect to image quality, slice thickness, and different pulse sequences. This MRI biomarker approach could be used to evaluate neuroprotection in preHD.

title: Automated structural imaging analysis detects premanifest XXXX within 1 year.

answer: @entity2


abstract: BACKGROUND: The aim of this study was to examine the role of Hh- @entity9 signaling in oral and @entity4 (SCC). The role of this signaling pathway in SCC formation has not yet been elucidated. METHODS: Sixty-four tissue and blood samples were collected from 60 @entity0 with SCC, all @entity3 and @entity2 users. An additional six buccal mucosa tissue samples were collected from nonsmokers and nondrinkers as control tissue. RESULTS: Hedgehog- @entity9 pathway components were associated with clinical and pathologic features. Broders' grade and N stage were associated with higher @entity6 and lower @entity9 expression. @entity1 stage was negatively associated with @entity7 expression, and @entity1 size was positively associated with @entity5 expression. @entity6 and @entity8 were frequently detected in the surrounding stroma. @entity6 was found to be correlated with @entity5 expression, as well as with survivin expression. CONCLUSIONS: The signaling pathway is activated in SCC and inducible in vitro by @entity8 protein.

title: Hh- @entity9 signaling pathway activity in oral and XXXX .

answer: @entity4


abstract: BACKGROUND: The aim of this study was to examine the role of Hh- @entity9 signaling in oral and @entity4 (SCC). The role of this signaling pathway in SCC formation has not yet been elucidated. METHODS: Sixty-four tissue and blood samples were collected from 60 @entity0 with SCC, all @entity3 and @entity2 users. An additional six buccal mucosa tissue samples were collected from nonsmokers and nondrinkers as control tissue. RESULTS: Hedgehog- @entity9 pathway components were associated with clinical and pathologic features. Broders' grade and N stage were associated with higher @entity6 and lower @entity9 expression. @entity1 stage was negatively associated with @entity7 expression, and @entity1 size was positively associated with @entity5 expression. @entity6 and @entity8 were frequently detected in the surrounding stroma. @entity6 was found to be correlated with @entity5 expression, as well as with survivin expression. CONCLUSIONS: The signaling pathway is activated in SCC and inducible in vitro by @entity8 protein.

title: Hh- XXXX signaling pathway activity in oral and @entity4 .

answer: @entity9


abstract: @entity2 is a comparatively rare type of @entity1 found in primary and mixed dentition. It not only adversely affects chewing and muscle functions, but also impairs normal growth and development of the mandible. This report describes the therapeutic results of a @entity0 with bilateral @entity2 in early mixed dentition after using a bonded constriction quad-helix appliance. The @entity0 , a @entity0 aged 9 years and 2 months, first visited our hospital after occlusal abnormality in the molar region was detected at a local dental clinic. Case analysis resulted in a diagnosis of bilateral @entity2 with slight mandibular retrognathism. Treatment objectives were to reduce the arch width of the maxillary dentition and expand the mandibular arch in order to establish and stabilize molar occlusion and to achieve a Class I molar relation and appropriate overbite and overjet. Treatment comprised covering the occlusal surface of the maxillary molars with resin and attaching a bonded constriction quad-helix appliance joined with a 0.040-inch quad-helix wire. A bi-helix appliance was also fixed to the mandibular dentition. @entity2 visibly improved after 5 months. Cervical headgear was then fitted and the @entity0 observed until eruption of the permanent dentition was complete. Class I molar relation was achieved after 2 years and 6 months, although spacing remained in the maxillary and mandibular dentitions. Treatment of bilateral @entity2 in mixed dentition by means of a bonded constriction quad-helix appliance attached to the maxillary dentition enabled effective bite opening and reduction in the width of maxillary arch independent of the @entity0 's cooperation, providing good therapeutic outcome in a short time period.

title: A case report of bilateral XXXX in early mixed dentition using bonded constriction quad-helix appliance.

answer: @entity2


abstract: The incidence of @entity2 in full term neonates during the last 5 years at Port Royal Maternity Hospital has been determined. Cerebral symptoms were classified in three grades; mild, moderate and severe. The study was concerned with gestational and obstetric causes of @entity1 . Babies with @entity6 , @entity4 and @entity5 were excluded. During the study the incidence of intra-partum @entity3 and still births was low, 2 to 2.5 per thousand births, and did not alter but there was a statistically significant reduction in the number of babies in the moderate and mildly affected groups. This may be due to improved obstetric practice. From 1974 to 1978 the incidence of fetal heart monitoring increased from 20 to 60 percent and since early 1977 amnioscopy has been performed in every @entity0 admitted. The incidence of cerebral symptoms may be an important method of assessing the quality of obstetric care. Serious accidents are becoming rare and therefore the incidence of mild or moderate cerebral symptoms is likely to be a better indicator of good obstetric care. In full term @entity0 perinatal factors are infrequently the cause of @entity1 .

title: [Incidence of XXXX in full term newborns in the last 5 years at Port Royal Maternity Hospital (author's transl)].

answer: @entity2


abstract: Dendritic cell (DC)-based vaccination is a promising strategy for @entity0 immunotherapy. However, clinical trials have indicated that immunosuppressive microenvironments induced by @entity0 profoundly suppress antitumor immunity and inhibit vaccine efficacy, resulting in @entity0 burdens. To overcome these obstacles and enhance the efficiency of DC vaccination, we generated interleukin (IL)-12- and granulocyte-macrophage colony-stimulating factor ( @entity4 )-coexpressing oncolytic adenovirus (Ad-/\B7/IL12/ @entity4 ) as suitable therapeutic adjuvant to eliminate immune suppression and promote DC function. By treating @entity0 with Ad-/\B7/IL12/ @entity4 prior to DC vaccination, DCs elicited greater antitumor effects than in response to either treatment alone. DC migration to draining lymph nodes (DLNs) dramatically increased in @entity1 treated with the combination therapy. This result was associated with upregulation of CC-chemokine ligand 21 (CCL21(+)) lymphatics in @entity0 treated with Ad-/\B7/IL12/ @entity4 . Moreover, the proportion of @entity3 (+)CD25(+) T-cells and @entity2 ( @entity2 ) expression was decreased in @entity1 treated with the combination therapy. Furthermore, combination therapy using immature DCs also showed effective antitumor effects when combined with Ad-/\B7/IL12/ @entity4 . The combination therapy had a remarkable therapeutic efficacy on large @entity0 . Taken together, oncolytic adenovirus coexpressing IL-12 and @entity4 in combination with DC vaccination has synergistic antitumor effects and can act as a potent adjuvant for promoting and optimizing DC vaccination.

title: Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and XXXX .

answer: @entity4


abstract: BACKGROUND AND AIM OF THE STUDY: The mitral annulus mechanics associated with @entity2 in pathologies such as mitral valve (MV) prolapse, @entity0 and dilative @entity1 remain unknown. The study aim was to investigate @entity3 ( @entity3 ) in the dilated annulus and in the displaced papillary muscles due to these pathological conditions. METHODS: Ten porcine MVs were harvested and mounted on a MV closure test rig with the papillary muscles held in the slack, normal, and taut positions. The MV annulus tissue rested on top of a plastic ring on which it could slide freely. The annulus was held by strings in the periphery during valve closure under hydrostatic trans-mitral pressure. The string tensions were measured, and further divided by string spacing to obtain the @entity3 . Three annuli of normal, 25% dilated and 50% dilated annulus sizes were used. RESULTS: The @entity3 was lowest at the commissural segment of the annulus, but increased towards the anterior and posterior segments, with a greater increase towards the anterior segment than towards the posterior. The @entity3 increased with the increase of the apical PM displacement from the slack to normal, and then taut position in the commissural segment of the annulus. Although the @entity3 increased with annulus area, the increase was less pronounced in the commissural segment than in the anterior and posterior segments. CONCLUSION: There is a significant difference in @entity3 values between a normal and prolapsed MV, and between a normal MV and a MV with displaced papillary muscles. This difference suggests that @entity2 is a consequence and MV counteraction of imbalanced annular mechanics between the @entity3 and myocardial force.

title: Mitral valve annulus tension and the mechanism of XXXX : an in-vitro study.

answer: @entity2


abstract: PURPOSE: The objective of this study was to report the experience acquired at the Seoul National University Hospital with Holmium Laser Enucleation of Prostate (HoLEP), combined with mechanical morcellation for symptomatic @entity1 ( @entity1 ). METHODS: A retrospective review was performed on the clinical data of 309 consecutive @entity0 who underwent HoLEP at our institution between July 2008 and June 2010. All @entity0 were evaluated preoperatively for prostate volume by transrectal ultrasound, maximum urinary flow rate (Qmax), International Prostate Symptoms Score (IPSS) and quality of life (QoL) score. Peri- and postoperative parameters were evaluated and @entity0 were followed-up at 1-, 3-, 6-, and 12- months with the aforementioned investigations. RESULTS: The @entity0 ' mean age was 68.3 (  6.5) years and mean prostate volume was 55.6 (  23.6) mL. Mean enucleation time was 56.2 (  25.1) minutes, mean morcellation time was 11.3 (  9.5) minutes, and the mean resected weight of the prostate was 20.8 (  16.9) g. The mean catheter indwelling period was 1.9 (  1.7) days and mean hospital stay was 2.9 (  1.5) days. Significant improvement was noted in Qmax, IPSS, and QoL at the 1-year follow-up compared with baseline (P<0.01). At 1 month 17.2% of @entity0 complained of irritative urinary symptoms, which were typically self-limiting within 3 months. Transient @entity2 was reported in 15.2% of @entity0 . No @entity0 experienced persistent obstructive symptoms that required reoperation. CONCLUSIONS: Our study showed that HoLEP is a safe and effective therapeutic modality for @entity1 .

title: Holmium laser enucleation of prostate for XXXX : seoul national university hospital experience.

answer: @entity1


abstract: PURPOSE: We evaluated the factors that affect the improvement of the initial peak flow rate after transurethral resection of the prostate (TURP) or photoselective vaporization of the prostate ( @entity4 ) for @entity1 ( @entity1 ) @entity0 by using noninvasive tools. METHODS: One hundred and twenty seven @entity1 @entity0 who had undergone TURP or @entity4 between January 2005 and May 2009 were evaluated. They were divided into 2 groups: the postoperative initial peak urinary flow rate (Qmax) was less than 10 mL/sec (Group 1; n=37, TURP=11, @entity4 =26) and more than 10 mL/sec (Group 2; n=90, TURP=41, @entity4 =49). We confirmed the @entity0 ' preoperative check lists. The check list were the international prostate symptom score (IPSS), the quality of life score, a past history of acute urinary retention (AUR), body mass index and/or @entity3 , the serum prostate-specific antigen (PSA) level and the prostate volume, the prostate transitional zone volume and @entity2 . The initial Qmax was measured at the outpatient clinic one week after discharge. RESULTS: The improvement rate was not significant difference between the TURP group (78.8%) and the @entity4 group (65.3%). The efficacy parameters were the IPSS-storage symptom score, the prostate volume, the PSA level and a past history of AUR. The IPSS-storage symptom scores of Group 1 (12.3  3.3) was higher than those of Group 2 (10.5  1.7). The prostate volume of Group 2 (42.3  16.6 g) was bigger than that of Group 1 (36.6  7.8 g). The PSA level of Group 2 (3.8  2.6 ng/mL) was higher than that of Group 1 (2.6  2.6 ng/mL). A past history of AUR in Group 1 (35.1%) was more prevalent than that of Group 2 (15.6%). CONCLUSIONS: The non-invasive factors affecting the initial Qmax after TURP or @entity4 were the IPSS-storage symptom score, the prostate volume and a past history of AUR. Accordingly, in @entity0 who have a higher IPSS-storage symptom score, a smaller prostate volume and a history of AUR, there might be a detrimental effect on the initial Qmax after TURP or @entity4 . These factors might also be used as long-term prognostic factors.

title: Factors affecting the improvement of the initial peak urinary flow rate after transurethral resection of the prostate or photoselective vaporization of the prostate for treating XXXX .

answer: @entity1


abstract: OBJECTIVES: Chronic rhinosinusitis may be accompanied by impaired immunity despite normal levels of serum immunoglobulins. Immune responses in @entity2 @entity0 have previously been evaluated using polysaccharide vaccines. Our AIM was to assess the immune status by evaluating responses to diphtheria and @entity1 vaccine. METHODS: Specific antibodies were measured before and 2 weeks after vaccination in 25 @entity0 with chronic or recurrent @entity2 and in 30 healthy individuals. The mean age of the @entity0 was 46 years and that of healthy controls 43 years. RESULTS: After vaccination the @entity0 had on average 4.08-fold lower responses to diphtheria toxoid and 2.20-fold lower responses to @entity1 than the controls. Fourteen out of 25 patients had antibody levels that did not reach the 95% normal distribution range of healthy controls after either diphtheria or @entity1 vaccination. All the @entity0 had normal levels of serum immunoglobulins. CONCLUSIONS: A significant proportion of @entity0 with persisting symptoms of rhinosinisitis may have impaired responses to protein vaccines. Responses to protein vaccines may be used to evaluate immune function of @entity2 @entity0 .

title: Antibody responses to XXXX and diphtheria vaccine in chronic and recurrent rhinosinusitis.

answer: @entity1


abstract: @entity4 ( @entity4 ) of colorectal origin is associated with a poor prognosis. However, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is available for a selected group of @entity4 @entity0 , which significantly increases overall survival rates up to 30%. As a consequence, there is substantial room for improvement. @entity1 targeting is expected to improve the treatment efficacy of @entity3 ( @entity3 ) further through 1) more sensitive preoperative @entity1 detection, thus reducing overtreatment; 2) better intraoperative detection and surgical elimination of residual disease using @entity1 -specific intraoperative imaging; and 3) @entity1 -specific targeted therapeutics. This review focuses, in particular, on the development of @entity1 -targeted imaging agents. A large number of biomarkers are known to be upregulated in @entity3 . However, to date, no validated criteria have been described for the selection of the most promising biomarkers for @entity1 targeting. Such a scoring system might improve the selection of the correct biomarker for imaging purposes. In this review, we present the TArget Selection Criteria (TASC) scoring system for selection of potential biomarkers for @entity1 -targeted imaging. By applying TASC to biomarkers for @entity3 , we identified seven biomarkers (carcinoembryonic antigen, CXC chemokine receptor 4, @entity5 , epithelial cell adhesion molecule, matrix metalloproteinases, @entity6 , and @entity2 ) that seem most suitable for @entity1 -targeted imaging applications in @entity3 . Further cross-validation studies in @entity3 and other @entity1 types are necessary to establish its definitive value.

title: Selecting Potential Targetable Biomarkers for Imaging Purposes in XXXX Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.

answer: @entity3


abstract: PURPOSE: Modest long-term success is one of the most disappointing issues facing patients undergoing anti- @entity1 surgery. Herein we introduce a novel surgical modification of the vaginal sling to address the mechanisms that may lead to a reduction in the success rate at the long-term follow-up. MATERIALS AND METHODS: Twenty-three female @entity0 with mean age of 48.2 years (range, 22-73 years) underwent anti- @entity1 surgery to correct their stress urinary @entity1 (SUI) between August 2006 and January 2008. The in situ anterior vaginal wall sling, reinforced with equi-size monofilament @entity3 tape, was used as an anti- @entity1 surgical procedure. The mean follow-up period was 30.2 months (range, 24-38 months). RESULTS: The surgical technique was successful in 22 @entity0 (95.65%); 20 of them were cured and 2 @entity0 showed clinical improvements. Urinary retention was observed in one @entity0 (4.34%), which was resolved after decreasing the tension of the suspension sutures. No significant post-voiding residue was detected postoperatively. CONCLUSIONS: Cost-effectiveness and a low risk of @entity2 , due to the presence of intervening vaginal mucosa, are important advantages of this technique. Long-term success is expected, because relaxation of the non-tension-free suspension sutures and dislocation of the midurethral sling are less likely.

title: How to achieve long-term success in the treatment of female urinary stress XXXX ? Novel modification on vaginal sling.

answer: @entity1


abstract: INTRODUCTION: @entity5 is an @entity1 with major co-morbidities. It has recently been suggested that @entity2 may be the result of systemic @entity1 . We aimed to explore the association between systemic @entity1 and symptoms of @entity2 and @entity6 in @entity0 with mainly moderate and clinically stable @entity5 using a range of inflammatory biomarkers, 2 @entity2 and 2 @entity6 scales. METHOD: We assessed 120 @entity0 with moderate @entity5 (FEV1% 52, @entity0 62%, age 66). @entity2 was assessed using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester @entity6 (MCFS) and the Borg scale before and after 6MWT. We measured systemic @entity3 , @entity7 , @entity3 -R1, @entity3 -R2 and @entity4 . RESULTS: A multivariate linear model of all biomarkers showed that @entity3 only had a positive correlation with BASDEC @entity2 score (p = 0.007). @entity3 remained positively correlated with @entity2 (p = 0.024) after further adjusting for @entity3 -R1, @entity3 -R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body mass and body composition to the model @entity3 was still associated with the BASDEC score (p = 0.044). Furthermore, @entity0 with higher @entity3 level (> 3 pg/ml, n = 7) had higher mean CES-D @entity2 score than the rest of the sample (p = 0.03). Borg @entity6 score at baseline were weakly correlated with @entity3 and @entity7 , and with @entity3 only after 6MWT. @entity0 with higher @entity3 had more @entity6 after 6MWD (p = 0.054). CONCLUSION: This study indicates a possible association between @entity3 and two frequent and major co-morbidities in @entity5 ; i.e., @entity2 and @entity6 .

title: Biomarkers of systemic @entity1 and XXXX and @entity6 in moderate clinically stable @entity5 .

answer: @entity2


abstract: INTRODUCTION: @entity5 is an @entity1 with major co-morbidities. It has recently been suggested that @entity2 may be the result of systemic @entity1 . We aimed to explore the association between systemic @entity1 and symptoms of @entity2 and @entity6 in @entity0 with mainly moderate and clinically stable @entity5 using a range of inflammatory biomarkers, 2 @entity2 and 2 @entity6 scales. METHOD: We assessed 120 @entity0 with moderate @entity5 (FEV1% 52, @entity0 62%, age 66). @entity2 was assessed using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester @entity6 (MCFS) and the Borg scale before and after 6MWT. We measured systemic @entity3 , @entity7 , @entity3 -R1, @entity3 -R2 and @entity4 . RESULTS: A multivariate linear model of all biomarkers showed that @entity3 only had a positive correlation with BASDEC @entity2 score (p = 0.007). @entity3 remained positively correlated with @entity2 (p = 0.024) after further adjusting for @entity3 -R1, @entity3 -R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body mass and body composition to the model @entity3 was still associated with the BASDEC score (p = 0.044). Furthermore, @entity0 with higher @entity3 level (> 3 pg/ml, n = 7) had higher mean CES-D @entity2 score than the rest of the sample (p = 0.03). Borg @entity6 score at baseline were weakly correlated with @entity3 and @entity7 , and with @entity3 only after 6MWT. @entity0 with higher @entity3 had more @entity6 after 6MWD (p = 0.054). CONCLUSION: This study indicates a possible association between @entity3 and two frequent and major co-morbidities in @entity5 ; i.e., @entity2 and @entity6 .

title: Biomarkers of systemic @entity1 and @entity2 and XXXX in moderate clinically stable @entity5 .

answer: @entity6


abstract: INTRODUCTION: @entity5 is an @entity1 with major co-morbidities. It has recently been suggested that @entity2 may be the result of systemic @entity1 . We aimed to explore the association between systemic @entity1 and symptoms of @entity2 and @entity6 in @entity0 with mainly moderate and clinically stable @entity5 using a range of inflammatory biomarkers, 2 @entity2 and 2 @entity6 scales. METHOD: We assessed 120 @entity0 with moderate @entity5 (FEV1% 52, @entity0 62%, age 66). @entity2 was assessed using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester @entity6 (MCFS) and the Borg scale before and after 6MWT. We measured systemic @entity3 , @entity7 , @entity3 -R1, @entity3 -R2 and @entity4 . RESULTS: A multivariate linear model of all biomarkers showed that @entity3 only had a positive correlation with BASDEC @entity2 score (p = 0.007). @entity3 remained positively correlated with @entity2 (p = 0.024) after further adjusting for @entity3 -R1, @entity3 -R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body mass and body composition to the model @entity3 was still associated with the BASDEC score (p = 0.044). Furthermore, @entity0 with higher @entity3 level (> 3 pg/ml, n = 7) had higher mean CES-D @entity2 score than the rest of the sample (p = 0.03). Borg @entity6 score at baseline were weakly correlated with @entity3 and @entity7 , and with @entity3 only after 6MWT. @entity0 with higher @entity3 had more @entity6 after 6MWD (p = 0.054). CONCLUSION: This study indicates a possible association between @entity3 and two frequent and major co-morbidities in @entity5 ; i.e., @entity2 and @entity6 .

title: Biomarkers of systemic @entity1 and @entity2 and @entity6 in moderate clinically stable XXXX .

answer: @entity5


abstract: INTRODUCTION: @entity5 is an @entity1 with major co-morbidities. It has recently been suggested that @entity2 may be the result of systemic @entity1 . We aimed to explore the association between systemic @entity1 and symptoms of @entity2 and @entity6 in @entity0 with mainly moderate and clinically stable @entity5 using a range of inflammatory biomarkers, 2 @entity2 and 2 @entity6 scales. METHOD: We assessed 120 @entity0 with moderate @entity5 (FEV1% 52, @entity0 62%, age 66). @entity2 was assessed using the BASDEC and CES-D scales. Fatigue was assessed using the Manchester @entity6 (MCFS) and the Borg scale before and after 6MWT. We measured systemic @entity3 , @entity7 , @entity3 -R1, @entity3 -R2 and @entity4 . RESULTS: A multivariate linear model of all biomarkers showed that @entity3 only had a positive correlation with BASDEC @entity2 score (p = 0.007). @entity3 remained positively correlated with @entity2 (p = 0.024) after further adjusting for @entity3 -R1, @entity3 -R2, 6MWD, FEV1%, and pack-years. Even after adding the MCFS score, body mass and body composition to the model @entity3 was still associated with the BASDEC score (p = 0.044). Furthermore, @entity0 with higher @entity3 level (> 3 pg/ml, n = 7) had higher mean CES-D @entity2 score than the rest of the sample (p = 0.03). Borg @entity6 score at baseline were weakly correlated with @entity3 and @entity7 , and with @entity3 only after 6MWT. @entity0 with higher @entity3 had more @entity6 after 6MWD (p = 0.054). CONCLUSION: This study indicates a possible association between @entity3 and two frequent and major co-morbidities in @entity5 ; i.e., @entity2 and @entity6 .

title: Biomarkers of systemic XXXX and @entity2 and @entity6 in moderate clinically stable @entity5 .

answer: @entity1


abstract: Clinical studies have shown that negative symptoms of @entity1 unresponsive to antipsychotic given alone can improve after augmentation with SSRI antidepressant. Laboratory investigations into the mechanism of this synergism showed that co-administration of SSRI and antipsychotic produces changes in @entity2 (A) receptor and related systems, which differ from the effects of each drug alone. To examine the clinical relevance of these findings, the current study examined the effects of SSRI augmentation treatment on @entity2 (A) receptor and related systems in @entity1 @entity0 . @entity1 @entity0 with high levels of negative symptoms unresponsive to antipsychotic treatment received add-on @entity4 (100 mg/d). Blood was taken before and 1, 3 and 6 wk after adding @entity4 and peripheral mononuclear cells (PMC) isolated. RNA encoding for @entity2 (A)b3, @entity5 , and 5-HT7 receptors, PKCb2, and @entity3 ( @entity3 ) was assayed with real-time RT-PCR. Plasma @entity3 protein was assayed using ELISA. Clinical symptoms were assessed with validated rating scales. We found significant increase in mRNA encoding for @entity2 (A)b3 and 5- @entity5 , 5-HT7 receptors and @entity3 and a reduction in PKCb2 mRNA. Plasma @entity3 protein concentrations were increased. There were significant correlations among the genes. Clinical symptoms improved significantly. mRNA expression of PKCb2, @entity5 and 5-HT7 showed significant associations with clinical symptoms. Combined SSRI+antipsychotic treatment is associated with changes in @entity2 (A) receptor and in related signalling systems in @entity0 . These changes may be part of the mechanism of clinically effective drug action and may prove to be biomarkers of pharmacological response.

title: SSRI augmentation of antipsychotic alters expression of @entity2 (A) receptor and related genes in PMC of XXXX @entity0 .

answer: @entity1


abstract: Clinical studies have shown that negative symptoms of @entity1 unresponsive to antipsychotic given alone can improve after augmentation with SSRI antidepressant. Laboratory investigations into the mechanism of this synergism showed that co-administration of SSRI and antipsychotic produces changes in @entity2 (A) receptor and related systems, which differ from the effects of each drug alone. To examine the clinical relevance of these findings, the current study examined the effects of SSRI augmentation treatment on @entity2 (A) receptor and related systems in @entity1 @entity0 . @entity1 @entity0 with high levels of negative symptoms unresponsive to antipsychotic treatment received add-on @entity4 (100 mg/d). Blood was taken before and 1, 3 and 6 wk after adding @entity4 and peripheral mononuclear cells (PMC) isolated. RNA encoding for @entity2 (A)b3, @entity5 , and 5-HT7 receptors, PKCb2, and @entity3 ( @entity3 ) was assayed with real-time RT-PCR. Plasma @entity3 protein was assayed using ELISA. Clinical symptoms were assessed with validated rating scales. We found significant increase in mRNA encoding for @entity2 (A)b3 and 5- @entity5 , 5-HT7 receptors and @entity3 and a reduction in PKCb2 mRNA. Plasma @entity3 protein concentrations were increased. There were significant correlations among the genes. Clinical symptoms improved significantly. mRNA expression of PKCb2, @entity5 and 5-HT7 showed significant associations with clinical symptoms. Combined SSRI+antipsychotic treatment is associated with changes in @entity2 (A) receptor and in related signalling systems in @entity0 . These changes may be part of the mechanism of clinically effective drug action and may prove to be biomarkers of pharmacological response.

title: SSRI augmentation of antipsychotic alters expression of XXXX (A) receptor and related genes in PMC of @entity1 @entity0 .

answer: @entity2


abstract: Clinical studies have shown that negative symptoms of @entity1 unresponsive to antipsychotic given alone can improve after augmentation with SSRI antidepressant. Laboratory investigations into the mechanism of this synergism showed that co-administration of SSRI and antipsychotic produces changes in @entity2 (A) receptor and related systems, which differ from the effects of each drug alone. To examine the clinical relevance of these findings, the current study examined the effects of SSRI augmentation treatment on @entity2 (A) receptor and related systems in @entity1 @entity0 . @entity1 @entity0 with high levels of negative symptoms unresponsive to antipsychotic treatment received add-on @entity4 (100 mg/d). Blood was taken before and 1, 3 and 6 wk after adding @entity4 and peripheral mononuclear cells (PMC) isolated. RNA encoding for @entity2 (A)b3, @entity5 , and 5-HT7 receptors, PKCb2, and @entity3 ( @entity3 ) was assayed with real-time RT-PCR. Plasma @entity3 protein was assayed using ELISA. Clinical symptoms were assessed with validated rating scales. We found significant increase in mRNA encoding for @entity2 (A)b3 and 5- @entity5 , 5-HT7 receptors and @entity3 and a reduction in PKCb2 mRNA. Plasma @entity3 protein concentrations were increased. There were significant correlations among the genes. Clinical symptoms improved significantly. mRNA expression of PKCb2, @entity5 and 5-HT7 showed significant associations with clinical symptoms. Combined SSRI+antipsychotic treatment is associated with changes in @entity2 (A) receptor and in related signalling systems in @entity0 . These changes may be part of the mechanism of clinically effective drug action and may prove to be biomarkers of pharmacological response.

title: SSRI augmentation of antipsychotic alters expression of @entity2 (A) receptor and related genes in PMC of @entity1 XXXX .

answer: @entity0


abstract: OBJECT: The normalization of @entity4 ( @entity4 ) in @entity0 with severe @entity2 ( @entity2 ) is assumed to limit secondary @entity7 and improve outcome. Despite evidence-based recommendations for monitoring and treatment of @entity4 , there are few studies that show an association between response to @entity4 -directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to @entity4 -lowering therapy on risk of @entity3 within the first 2 weeks of injury in @entity0 who sustained @entity2 and are older than 16 years. METHODS: The current study is based on 1426 @entity0 with severe @entity2 (Glasgow @entity6 Scale [GCS] score < 9) of whom 388 were treated for @entity4 (> 25 mm Hg) between 2000 and 2008 at 22 @entity1 centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and @entity5 , which are all known early prognostic indicators of @entity3 . Treatment of @entity4 consisted of administration of @entity8 , hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting @entity4 response to treatment and predicting @entity3 at 2 weeks were evaluated using logistic regression analyses. RESULTS: Increasing age and fewer hours of @entity4 on Day 1 were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to @entity4 -lowering therapy (p = 0.03), younger age (p < 0.0001), fewer hours of @entity4 (p < 0.0001), and absence of arterial @entity5 on Day 1 (p = 0.001) significantly predicted reduced risk of @entity3 . CONCLUSIONS: @entity0 who responded to @entity4 -lowering treatment had a 64% lower risk of @entity3 at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of @entity3 .

title: Response to intracranial hypertension treatment as a predictor of @entity3 in @entity0 with severe XXXX .

answer: @entity2


abstract: OBJECT: The normalization of @entity4 ( @entity4 ) in @entity0 with severe @entity2 ( @entity2 ) is assumed to limit secondary @entity7 and improve outcome. Despite evidence-based recommendations for monitoring and treatment of @entity4 , there are few studies that show an association between response to @entity4 -directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to @entity4 -lowering therapy on risk of @entity3 within the first 2 weeks of injury in @entity0 who sustained @entity2 and are older than 16 years. METHODS: The current study is based on 1426 @entity0 with severe @entity2 (Glasgow @entity6 Scale [GCS] score < 9) of whom 388 were treated for @entity4 (> 25 mm Hg) between 2000 and 2008 at 22 @entity1 centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and @entity5 , which are all known early prognostic indicators of @entity3 . Treatment of @entity4 consisted of administration of @entity8 , hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting @entity4 response to treatment and predicting @entity3 at 2 weeks were evaluated using logistic regression analyses. RESULTS: Increasing age and fewer hours of @entity4 on Day 1 were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to @entity4 -lowering therapy (p = 0.03), younger age (p < 0.0001), fewer hours of @entity4 (p < 0.0001), and absence of arterial @entity5 on Day 1 (p = 0.001) significantly predicted reduced risk of @entity3 . CONCLUSIONS: @entity0 who responded to @entity4 -lowering treatment had a 64% lower risk of @entity3 at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of @entity3 .

title: Response to intracranial hypertension treatment as a predictor of XXXX in @entity0 with severe @entity2 .

answer: @entity3


abstract: OBJECT: The normalization of @entity4 ( @entity4 ) in @entity0 with severe @entity2 ( @entity2 ) is assumed to limit secondary @entity7 and improve outcome. Despite evidence-based recommendations for monitoring and treatment of @entity4 , there are few studies that show an association between response to @entity4 -directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to @entity4 -lowering therapy on risk of @entity3 within the first 2 weeks of injury in @entity0 who sustained @entity2 and are older than 16 years. METHODS: The current study is based on 1426 @entity0 with severe @entity2 (Glasgow @entity6 Scale [GCS] score < 9) of whom 388 were treated for @entity4 (> 25 mm Hg) between 2000 and 2008 at 22 @entity1 centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and @entity5 , which are all known early prognostic indicators of @entity3 . Treatment of @entity4 consisted of administration of @entity8 , hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting @entity4 response to treatment and predicting @entity3 at 2 weeks were evaluated using logistic regression analyses. RESULTS: Increasing age and fewer hours of @entity4 on Day 1 were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to @entity4 -lowering therapy (p = 0.03), younger age (p < 0.0001), fewer hours of @entity4 (p < 0.0001), and absence of arterial @entity5 on Day 1 (p = 0.001) significantly predicted reduced risk of @entity3 . CONCLUSIONS: @entity0 who responded to @entity4 -lowering treatment had a 64% lower risk of @entity3 at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of @entity3 .

title: Response to intracranial hypertension treatment as a predictor of @entity3 in XXXX with severe @entity2 .

answer: @entity0


abstract: PURPOSE: Arthroscopic knee surgery is done in outpatient settings; however, @entity2 is a major barrier for discharge and limits early rehabilitation. The efficacy of intraarticular application of @entity6 , @entity4 and @entity7 , with placebo on @entity2 after arthroscopic meniscectomy was evaluated. METHODS: One hundred and twenty ASA status I-II @entity0 undergoing elective arthroscopic meniscectomy were included in this randomized, single blind, prospective study. Group-M (GM) @entity0 had intraarticular 500 mg of @entity6 in 20 ml saline; group-P (GP) @entity0 had intraarticular 20 ml saline; group-LB (GLB) @entity0 had 100 mg @entity4 in 20 ml (0.5%); group-L (GL) @entity0 had intraarticular 8 mg of @entity7 in 20 ml saline before tourniquet deflation. Postoperative analgesia was maintained by iv @entity3 PCA 0.3 mg kg(-1) bolus dose and 5 min lockout time during the first 4 h and later with @entity5 500 mg. The NRS values at rest and at exercise and analgesic consumptions were evaluated at the end of the first, second and 4th hours and at the 12th, 24th and 48th hours by an anaesthesiologist who was blind to the solutions administered. RESULTS: All study groups provided analgesia when compared with GP. The first request of oral analgesic time was shorter in GP. Analgesic consumptions of GP were higher than other groups. @entity1 scores during 1, 2 and 4 h postoperatively were lower in all study groups than the GP. CONCLUSION: Administration of all the drugs provided better analgesia than placebo and the most effective one was @entity7 .

title: Comparison of efficacy of intraarticular application of magnesium, @entity4 and XXXX with placebo in arthroscopic surgery.

answer: @entity7


abstract: PURPOSE: Arthroscopic knee surgery is done in outpatient settings; however, @entity2 is a major barrier for discharge and limits early rehabilitation. The efficacy of intraarticular application of @entity6 , @entity4 and @entity7 , with placebo on @entity2 after arthroscopic meniscectomy was evaluated. METHODS: One hundred and twenty ASA status I-II @entity0 undergoing elective arthroscopic meniscectomy were included in this randomized, single blind, prospective study. Group-M (GM) @entity0 had intraarticular 500 mg of @entity6 in 20 ml saline; group-P (GP) @entity0 had intraarticular 20 ml saline; group-LB (GLB) @entity0 had 100 mg @entity4 in 20 ml (0.5%); group-L (GL) @entity0 had intraarticular 8 mg of @entity7 in 20 ml saline before tourniquet deflation. Postoperative analgesia was maintained by iv @entity3 PCA 0.3 mg kg(-1) bolus dose and 5 min lockout time during the first 4 h and later with @entity5 500 mg. The NRS values at rest and at exercise and analgesic consumptions were evaluated at the end of the first, second and 4th hours and at the 12th, 24th and 48th hours by an anaesthesiologist who was blind to the solutions administered. RESULTS: All study groups provided analgesia when compared with GP. The first request of oral analgesic time was shorter in GP. Analgesic consumptions of GP were higher than other groups. @entity1 scores during 1, 2 and 4 h postoperatively were lower in all study groups than the GP. CONCLUSION: Administration of all the drugs provided better analgesia than placebo and the most effective one was @entity7 .

title: Comparison of efficacy of intraarticular application of magnesium, XXXX and @entity7 with placebo in arthroscopic surgery.

answer: @entity4


abstract: @entity3 is associated with adverse @entity0 development, but little is known about the effects of paternal @entity3 . This pilot study estimated the prevalence of paternal @entity3 and mood state, and assessed the relationship between paternal mood and @entity0 temperament. The @entity0 in the study were 98 fathers of newborn babies. Fathers were initially screened for @entity3 mood ( @entity1 and @entity3 scale, and @entity3 scale), and at 6 months parental mood, @entity0 temperament, couple relationship quality, @entity2 use, adverse life events, parenting, and demographics were recorded. @entity0 fussiness was analysed in relation to paternal mood and other contextual factors using multiple regression. Of the 98 fathers, 48 (49%) completed @entity3 . Of these 48 fathers, 4 (8%) reported @entity3 above the cut-off for case definition. A total of 48% (N=19) completed measures at follow-up. In the adjusted model, higher paternal @entity3 scores, more traditional attitudes towards fathering, and increased recent life events were related to higher @entity0 fussiness scores; and better couple relationship quality was related to lower fussiness scores. This study showed that 1 in 12 fathers had @entity3 mood, and lower mood was associated with negative @entity0 temperament. Since the findings of this feasibility study were based on a small sample size the association of paternal mood and @entity0 development merits further study using a larger sample of fathers.

title: The association of paternal mood and XXXX temperament: A pilot study.

answer: @entity0


abstract: Adult cases with isolated @entity3 are very rare. We report a case with dumbbell-type @entity6 in the cervical spine. A 38-year-old @entity0 presented with moderate @entity4 of the right ring finger and right little finger and weakness of the right grip. Magnetic resonance imaging (MRI) showed an intra-spinal mass extending into the paravertebral area. The spinal cord was compressed by the lesion, which was isointense with the spinal cord on both T1- and T2-weighted imaging. Homogenous enhancement was observed after @entity5 administration. These findings favored a preoperative diagnosis of a rare @entity1 , rather than @entity7 . @entity1 was performed through hemilaminectomy combined with facetectomy between C7 and T1. Histological examination and immunohistochemical testing led to a diagnosis of @entity6 . Two years after complete resection, MRI showed no recurrence. This appears to represent the first report of dumbbell-type @entity6 in the cervical spine. Total @entity2 is recommended because of the high potential risk of @entity1 recurrence around the central nervous system.

title: Dumbbell-type XXXX in the cervical spine of an adult.

answer: @entity6


abstract: OBJECTIVE: To determine the primary sites, clinical features, treatment, and outcome of 46 @entity1 with @entity5 metastatic to the orbits in southern China. METHODS: Retrospective review of medical records at a tertiary center in southern China between Jan 1, 1991 and Dec 31, 2008. RESULTS: The study included 35 males and 11 females, with an age range of 3-78  years (average 47  years). All of the @entity1 came from southern China. The left orbit was affected more frequently than the right orbit (3:2), and no cases were bilaterally involved. The most common primary @entity5 that metastasizes to the orbit is @entity8 (30.34%), followed by @entity2 (8.70%), @entity6 (6.52%), @entity0 (4.35%), @entity14 (4.35%), @entity10 (2.17%), @entity8 (2.17%), @entity8 (2.17%), mediastinum @entity8 (2.17%), other forms (6.52%), and unknown @entity8 (30.34%). Orbital @entity3 was the first sign of systemic @entity5 in 24 @entity1 (52.17%). The five most common clinical findings at the initial examination were @entity11 (65.22%), proptosis (63.04%), increased orbital pressure (54.35%), @entity12 (54.35%), and @entity13 (52.17%), followed by swollen eyelid (50%), visible mass or @entity4 (46%), @entity9 (41%), @entity17 , and @entity4 (35%), @entity7 (28%), @entity15 (20%), @entity16 (17%), and vasodilatation of the retina (7%). Primary treatment included surgical excision, radiotherapy, systemic chemotherapy, and observation. Among the @entity1 (78% of 46) with sufficient follow-up time (mean 20.7  months), 30.56% of them died of disseminated @entity3 . Twenty-five percent of them were in remission with no active metastases and 27.78% of them were living with active metastases. Overall, the mean survival time was 18  months (range, 5-38  months) after diagnosis of orbital @entity3 . CONCLUSIONS: The most common primary @entity5 that metastasizes to the orbit is @entity8 (30.34%), followed by @entity2 (8.70%) and @entity6 (6.52%) in southern China. Orbital @entity3 can display a variety of clinical features and should be considered in @entity1 with known systemic @entity5 . The systemic prognosis is generally poor.

title: Metastatic XXXX in southern China during an 18-year period.

answer: @entity5


abstract: INTRODUCTION AND HYPOTHESIS: The aim of the study was to determine whether a 6-week course of 5 mg of @entity2 used to treat mixed @entity1 , produces measurable changes in the appearance of the urethral sphincter. METHODS: Twenty-six @entity0 undergoing treatment for mixed @entity1 were recruited from a urogynaecology unit after failing to improve with conservative treatments and bladder drill. All underwent dual channel subtracted cystometry, which showed mixed urodynamic stress @entity1 and detrusor overactivity. All @entity0 underwent a 3D transperineal ultrasound before @entity2 therapy was started and after 6 weeks of treatment. The urethral length, width and volume of the smooth muscle and total sphincter volume were compared before and after the treatment. RESULTS: Clinically, 13 reported no improvement in either stress or urge @entity1 . Eight @entity0 reported improvement in their urgency symptoms but no benefit in their stress leakage. Four @entity0 reported resolution of both stress and urge @entity1 . One @entity0 reported worsening of her bladder symptoms. There was no significant change in the urethral length (p = 0.27), width (p = 0.50), volume of smooth muscle (p = 0.87) or total sphincter volume (p = 0.60) before and after treatment with @entity2 . CONCLUSIONS: A 6-week course of @entity2 resulted in no measurable changes in the appearance of the urethral sphincter.

title: The effect of XXXX on urethral sphincter morphology.

answer: @entity2


abstract: BACKGROUND: This study compared 1-year risk of @entity1 hospitalization and treatment costs in commercially insured @entity0 with @entity2 , treated with @entity7 , @entity6 , @entity3 , @entity4 or @entity5 . METHODS: This was a retrospective propensity score-matched cohort study using the Ingenix Lab/Rx integrated insurance claims dataset. @entity0 with @entity2 and 180 days of pre-index enrollment without antipsychotic exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma regression compared post-index costs between treatment groups. RESULTS: Compared to @entity7 , @entity6 , @entity3 and @entity4 had higher risks for hospitalization (hazard ratio 1.96, 1.55 and 1.56, respectively; p < 0.05); @entity5 had a numerically higher but not statistically different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for @entity7 compared with @entity6 (p = 0.004) and @entity4 (p = 0.007), but not compared to @entity3 (p = 0.29) or @entity5 (p = 0.80). Total healthcare costs were significantly lower for @entity7 compared to @entity4 (p = 0.040) but not other comparators. CONCLUSIONS: In commercially insured adults with @entity2 followed for 1 year after initiation of atypical antipsychotics, treatment with @entity7 was associated with a lower risk of @entity1 hospitalization than @entity6 , @entity4 , @entity3 and @entity5 , although this did not reach significance with the latter. @entity7 was also associated with significantly lower total healthcare costs than @entity4 , but not the other comparators.

title: One-year risk of @entity1 hospitalization and associated treatment costs in XXXX treated with atypical antipsychotics: a retrospective claims database analysis.

answer: @entity2


abstract: BACKGROUND: This study compared 1-year risk of @entity1 hospitalization and treatment costs in commercially insured @entity0 with @entity2 , treated with @entity7 , @entity6 , @entity3 , @entity4 or @entity5 . METHODS: This was a retrospective propensity score-matched cohort study using the Ingenix Lab/Rx integrated insurance claims dataset. @entity0 with @entity2 and 180 days of pre-index enrollment without antipsychotic exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma regression compared post-index costs between treatment groups. RESULTS: Compared to @entity7 , @entity6 , @entity3 and @entity4 had higher risks for hospitalization (hazard ratio 1.96, 1.55 and 1.56, respectively; p < 0.05); @entity5 had a numerically higher but not statistically different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for @entity7 compared with @entity6 (p = 0.004) and @entity4 (p = 0.007), but not compared to @entity3 (p = 0.29) or @entity5 (p = 0.80). Total healthcare costs were significantly lower for @entity7 compared to @entity4 (p = 0.040) but not other comparators. CONCLUSIONS: In commercially insured adults with @entity2 followed for 1 year after initiation of atypical antipsychotics, treatment with @entity7 was associated with a lower risk of @entity1 hospitalization than @entity6 , @entity4 , @entity3 and @entity5 , although this did not reach significance with the latter. @entity7 was also associated with significantly lower total healthcare costs than @entity4 , but not the other comparators.

title: One-year risk of XXXX hospitalization and associated treatment costs in @entity2 treated with atypical antipsychotics: a retrospective claims database analysis.

answer: @entity1